Intensity Therapeutics Inc (INTS) Stock Price, Quote & News

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Co...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 221 7381

Fax: 203 557 3023

Website: intensitytherapeutics.com

Address:

1 Enterprise Drive, Suite 430, Shelton, United States

TNNSTrade May. 8 at 8:18 PM

$INTS Everything seems on track. We just need to find some momentum. Enjoy the weekend!

1 · Reply

Pettechfl May. 7 at 10:47 PM

https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302766229.html $INTS

0 · Reply

joel12365 May. 6 at 8:56 PM

$INTS Two data sets in q3 Partner talks from 2024 Ints has more data than ever right now Continued talks q4 hopefully continued or progressive q1 Doubt they dilute a lot before we move up Good luck

0 · Reply

TNNSTrade May. 6 at 5:49 PM

$INTS Just waiting on data and publications. 👀

1 · Reply

DrAC99 May. 6 at 2:10 PM

$INTS Anything worth noting in this proxy vote? Looks like they’re approving the ability to sell more shares. Not sure if there’s any significance there.

1 · Reply

joel12365 May. 5 at 8:36 PM

$INTS hey everyone been stacking daily Lowering my average Intensity therapeutics reporting a q1 update soon. I am confident I am hopeful I hope partnerships continue discussion as we could do with more hands on deck -Joel

0 · Reply

Pettechfl May. 4 at 10:04 PM

$INTS https://www.foxnews.com/health/patients-remain-cancer-free-nearly-3-years-receiving-experimental-immunotherapy more good news for us.

0 · Reply

KayJ_ May. 4 at 9:03 PM

$BYAH $ADVB $ZDAI $INTS beinks

0 · Reply

DrAC99 May. 4 at 2:42 PM

$INTS Feels like a move one way or the other incoming this week..

0 · Reply

Masonic11 May. 2 at 9:32 PM

$ALP What would really behove this ticker: Is an update on the biochemical advancement of the cancer molecule, $INTS . They took parts of the company private. Portage. Come to the fukn table. Us legacy holders aren't stupid. These crooks have to get their shit together and have a unified advancement of subsidiarys. No mo smoke m mirrors. If you want to be a player on any front, get your shit together and don't give any wiggle room for these conglomerated retail shorts to fuk the global plans of advancement. You fukd up the shares with the ticker change. Make new news really count. Don't be behind the 8 ball, be the 8 ball...👽👽👽

1 · Reply

Intensity Therapeutics reports Q1 EPS (96c), consensus ($1.09)

May 7, 2026, 4:06 PM EDT - 2 days ago

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Apr 15, 2026, 9:15 AM EDT - 24 days ago

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

2026-03-30T20:00:12.000Z - 5 weeks ago

Intensity Therapeutics upgraded to Buy from Hold at Freedom Broker

Mar 27, 2026, 4:12 PM EDT - 6 weeks ago

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

2026-03-24T12:12:43.000Z - 6 weeks ago

Intensity Therapeutics issued new patent in the US

Mar 24, 2026, 8:00 AM EDT - 6 weeks ago

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

2026-03-13T11:12:24.000Z - 2 months ago

Intensity Therapeutics price target adjusted to $30 at Alliance Global

2026-03-12T11:36:30.000Z - 2 months ago

Intensity Therapeutics provides update on INVINCIBLE-4 Study

Mar 12, 2026, 7:30 AM EDT - 2 months ago

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

2026-03-06T12:50:53.000Z - 2 months ago

Intensity Therapeutics regains Nasdaq compliance

Mar 6, 2026, 7:47 AM EST - 2 months ago

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

2026-02-19T00:50:17.000Z - 2 months ago

Intensity Therapeutics Inc trading halted, news pending

2026-02-13T14:00:18.000Z - 3 months ago

Intensity Therapeutics announces reverse stock split

Feb 13, 2026, 8:58 AM EST - 3 months ago

Intensity Therapeutics Announces Reverse Stock Split

2026-01-13T12:55:38.000Z - 4 months ago

Intensity Therapeutics to ‘opportunistically raise additional capital’ in 2026

Jan 13, 2026, 7:47 AM EST - 4 months ago

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

2025-12-11T12:55:17.000Z - 5 months ago

Intensity Therapeutics to present two posters ay SABCS

Dec 11, 2025, 7:47 AM EST - 5 months ago

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

2025-12-05T12:35:32.000Z - 5 months ago

Intensity Therapeutics granted 180-day extension to regain Nasdaq compliance

Dec 5, 2025, 7:30 AM EST - 5 months ago

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 4, 2025, 7:47 AM EST - 5 months ago

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

2025-11-06T21:52:24.000Z - 6 months ago

Intensity Therapeutics reports Q3 EPS (6c) vs. (25c) last year

Nov 6, 2025, 4:02 PM EST - 6 months ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 9:00 AM EDT - 6 months ago

Intensity Therapeutics Transcript: Study Result

2025-10-31T12:10:36.000Z - 6 months ago

Intensity Therapeutics prices 5M shares at 80c in registered direct offering

Oct 31, 2025, 8:00 AM EDT - 6 months ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

2025-10-30T13:08:35.000Z - 6 months ago

Why Is Intensity Therapeutics Stock (INTS) Up 195% Today?

2025-10-30T11:40:25.000Z - 6 months ago

Intensity Therapeutics’ INT230-6 antitumor effect featured in published study

$Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal$

Oct 30, 2025, 7:30 AM EDT - 6 months ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Oct 22, 2025, 10:30 AM EDT - 7 months ago

Intensity Therapeutics Transcript: AGM 2025

2025-09-10T11:50:14.000Z - 8 months ago

Intensity Therapeutics pauses new patient enrollment in INVINCIBLE-4 trial

Sep 10, 2025, 7:47 AM EDT - 8 months ago

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 2, 2025, 7:47 AM EDT - 8 months ago

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-20T11:45:09.000Z - 9 months ago

Intensity Therapeutics price target lowered to $1.50 from $4 at Benchmark

2025-08-12T19:25:20.000Z - 9 months ago

Intensity Therapeutics upgraded to Buy from Hold at Brookline

Aug 12, 2025, 7:47 AM EDT - 9 months ago

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 7, 2025, 4:06 PM EDT - 9 months ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 7:47 AM EDT - 9 months ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Jul 17, 2025, 10:30 AM EDT - 10 months ago

Intensity Therapeutics Transcript: AGM 2025

Jun 30, 2025, 8:00 AM EDT - 11 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 11, 2025, 11:46 PM EDT - 11 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 4:06 PM EDT - 11 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 8:30 AM EDT - 11 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

May 29, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 28, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 13, 2025, 4:06 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Mar 13, 2025, 4:07 PM EDT - 1 year ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025, 8:00 AM EST - 1 year ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 17, 2024, 10:00 AM EDT - 1 year ago

Intensity Therapeutics Transcript: AGM 2024

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

May 15, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 10, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 2 years ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 9, 2024, 10:00 AM EDT - 2 years ago

Intensity Therapeutics Transcript: LD Micro Invitational XIV Conference

Apr 2, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 2 years ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Feb 21, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 8, 2023, 8:30 AM EST - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

TNNSTrade May. 8 at 8:18 PM

$INTS Everything seems on track. We just need to find some momentum. Enjoy the weekend!

1 · Reply

Pettechfl May. 7 at 10:47 PM

https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302766229.html $INTS

0 · Reply

joel12365 May. 6 at 8:56 PM

$INTS Two data sets in q3 Partner talks from 2024 Ints has more data than ever right now Continued talks q4 hopefully continued or progressive q1 Doubt they dilute a lot before we move up Good luck

0 · Reply

TNNSTrade May. 6 at 5:49 PM

$INTS Just waiting on data and publications. 👀

1 · Reply

DrAC99 May. 6 at 2:10 PM

$INTS Anything worth noting in this proxy vote? Looks like they’re approving the ability to sell more shares. Not sure if there’s any significance there.

1 · Reply

joel12365 May. 5 at 8:36 PM

0 · Reply

Pettechfl May. 4 at 10:04 PM

$INTS https://www.foxnews.com/health/patients-remain-cancer-free-nearly-3-years-receiving-experimental-immunotherapy more good news for us.

0 · Reply

KayJ_ May. 4 at 9:03 PM

$BYAH $ADVB $ZDAI $INTS beinks

0 · Reply

DrAC99 May. 4 at 2:42 PM

$INTS Feels like a move one way or the other incoming this week..

0 · Reply

Masonic11 May. 2 at 9:32 PM

1 · Reply

malphius May. 1 at 3:46 PM

$INTS $PLSE $ HUMA is about to squeeze. Just needs some volume. Legit company revolutionizing arterial repair and replacement. Markets are Trauma, Dialysis and CABG. FDA approved for trauma already. June catalyst for Dialysis. Check it out. Good hold too imo.

0 · Reply

SBEEE May. 1 at 12:40 PM

$INTS $60 million offering approved, CEO will get the paycheck tell they can and then shut down the company.

2 · Reply

SBEEE Apr. 30 at 12:37 PM

$INTS

0 · Reply

Jdhunter819 Apr. 29 at 6:32 PM

$INTS going to the moon 🌖

0 · Reply

joel12365 Apr. 29 at 2:35 PM

$INTS How many shares have we all got before may 7th Update comes Hopefully we get lovely updates At current market enterprise valuation we sit at a meer 1.3 million for intensity therapeutics 1.3million usd for intensity therapeutics business You hear correctly As long as cash hasn’t been used to crazily I’m happy to stack 4k shares hopefully before we go galactic Thanks

2 · Reply

basedman Apr. 28 at 11:48 PM

$INTS hello my love. I'm back. I know I walked away after last pump but I don't forget how much money you made me. I think it's time again. You're awfully low and have been quiet lately. Let me give you some bags tomorrow

1 · Reply

Atrain1189 Apr. 28 at 4:36 PM

$INTS completely dormant but holding these levels. Truly believe there is news coming in the next few weeks that makes this run to double digits and stay there

0 · Reply